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1. Introduction 
Mushrooms, a special group of macrofungi, are not plants and thus do not use 
photosynthesis for nutrient acquisition. Mushrooms are fleshy, have the spore-bearing 
fruiting body of fungi, and typically grow above ground on soil, or other food sources. Most 
mushrooms are Basidiomycota or Agaricomycetes. The fruiting body of mushrooms is an 
important food and is used in many cuisines worldwide. Additionally, several species have 
been consumed extensively as a crude drug or folk tonics; in East Asia, these mushrooms 
are considered as medicinal mushrooms. Some medicinal mushrooms can be cultured and 
are an abundant source of natural proteins and polysaccharides. These mushrooms have 
garnered considerable attention for clinical research and for modern scientific and medicinal 
researches investigating their biological functions (Kino et al., 1989). 
1.1 Functional mushrooms 
In recent decades, medicinal mushrooms have been used to improve human health and 
strengthen the immune system, which have become significant issues in medical and 
pharmacological researchers (Guillamon et al., 2010; Kwok et al., 2005). The activities that 
have been identified include immunomodulatory and hypocholesterolemic actions, and 
antitumor, anti-inflammatory, anti-allergic, anticoagulation, and antithrombin activity as 
well as fibrino(geno)lysis stimulation (Lu et al., 2010b; Wang et al., 1995). Based on the 
medicinal potentials of edible mushrooms, scientists and businesses have devoted 
considerable effort to increase the quality of cultivated mushroom. It’s estimated that 
approximately 14,000 species of mushrooms exist (Miles & Chang, 2004); as edible and 
medicinal mushrooms account for only a small proportion. More than 10 million metric tons 
of edible and medicinal mushrooms are cultivated annually worldwide. Products from 
cultivated mushrooms have been used extensively as food additives, health foods, and for 
medicinal purposes to treat cancers and circulatory disorders (Kim et al., 2003; Mao et al., 
2005; Park et al., 2001). Improvements in mushroom cultivation technology have brought 
countless benefits to commercial production and laboratory applications of mushroom. 
1.2 Bioactive compounds in mushrooms 
Many bioactive compounds, such as cordycepin, polysaccharides, polysaccharide-peptide 
complex, ergosterol, mannitol, peptides and protein/protease, in various mushrooms have 
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chemotherapeutic or medicinal activity (Das et al., 2010). The sources of these bioactive 
compounds include fruiting body, mycelia, cultivation broth, submerged cultivation 
mycelia and fermentation derivatives (Cheung, 1996; Fiore & Kakkar, 2003; Kwok et al., 
2005; Sugimoto et al., 2007; Wang et al., 1995; Wong et al., 2011; Wu et al., 2010, Yamamoto 
et al., 2005; Yoon et al., 2003). This chapter focuses on the fibrinolytic enzymes derived from 
medicinal mushrooms. The function and characterization of these fibrinolytic enzymes are 
described in detail. Technologies for purification and characterization of fibrinolytic enzyme 
from Schizophyllum commune are discussed. 
2. Haemostasis and antithrombotic studies 
Cardiovascular diseases are the leading cause of death worldwide. A common cause of 
cardiovascular diseases is abnormal fibrin accumulation in the blood vessels or a fibrin clot 
adhering to the unbroken vessel walls of the endoepithelium. An abnormal clot formation is 
called a “thrombus”. Thrombosis can stop blood circulation in vessels (arteries or veins), 
and may cause a hypoxiation syndrome such as acute myocardial infarction, high blood 
pressure, ischemic heart, and stroke (Mine et al., 2005). In response to the high mortality 
rates associated with thrombosis, antithrombotic studies and clinical therapies are 
progressing rapidly. 
2.1 Mechanisms of coagulation 
The balance of circulation blood in a liquid or clotted state is called haemostasis, which 
includes two complementary mechanisms: blood coagulation and fibrinolysis. 
Coagulation limits blood loss from a damaged vessel via clot formation. After the 
rehabilitation of the vessel’s endoepithelium, fibrinolysis system processes dissolve clots 
and recover circulating blood (Takada et al., 1994). When a blood vessel is damaged by 
external force (e.g. a cut or scrape), this damage induces the platelet activation and 
aggregation of clotting plasma proteins. Platelets adhere to the subendothelium and 
simultaneously activate a coagulation cascade that induces fibrin production (Heemskerk 
et al., 2002). This coagulation cascade is the outcome of multiple interdependent 
interactions among plasma proteins (tissue factors), platelets, prothrombin, thrombin, 
fibrinogen, and fibrin. Via the intrinsic and extrinsic pathways, soluble fibrinogen is 
converted into insoluble fibrin. Fibrins construct a mesh structure over the platelet plug, 
sealing the injury site (Gentry, 2004; Norris, 2003; Wolberg, 2007). 
2.2 Fibrinolysis 
Under normal conditions, fibrin clots formed in blood vessels should be disassembled 
rapidly and removed by the fibrinolysis system effectively. The key enzyme in the 
fibrinolysis system is plasmin, a serine protease, which is activated from proenzyme 
plasminogen via a tissue-type plasminogen activator (tPA) or a urinary plasminogen 
activator (u-PA) trigger. The fibrinolysis system is regulated by a number of orchestrated 
interactions between fibrin, specific inhibitors, and plasminogen; plasminogen activators are 
indeed necessary that generate clot degradation (Medved & Nieuwenhuizen, 2003). Collen 
(1999) demonstrated that a fibrin formation can trigger activation of fibrinolytic system and 
generate of active plasmin; the latter substance may then degrade fibrin into soluble fibrin 
degradation products (FDPs), followed by clot disintegration (Collen, 1999). 
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2.3 Clinical thrombolytic agents 
Pharmacologic dissolution of an established thrombus is now an accepted therapeutic 
approach for thrombotic occlusive disease. Intravenous infusion of commercial thrombolytic 
agents - plasminogen activators (PA), including recombinant tPA (r-tPA), u-PA, rokinase, 
streptokinase, and anisoylated plasminogen streptokinase-activator complex is effective in 
restoring blood flow in occluded arteries and veins (Liu et al., 2005). However, these agents 
are expensive and have a number of drawbacks, such as rapid degradation, uncontrollable 
acceleration of fibrinolysis and haemorrhage. Widespread systemic activation of fibrinolysis 
leads to potentially life-threatening side effects. To overcome these risks, a safer 
thrombolytic agent is need for treating thrombolytic processes. 
3. Overview of fibrinolytic enzymes  
Fibrinolytic enzymes have been found in natural sources. Their activity resembles that of 
plasmin, which can degrade fibrin and inhibit fibrin clot formation (Chen et al., 1991; 
Mihara et al., 1991; Sumi et al., 1987). Moreover, some fibrinolytic enzymes exhibit activity 
similar to that of a PA. These enzymes may have great potential for antithrombotic therapy. 
Their specific characteristics, such as fibrinolysis, fibrinogenolysis and the proteolytic effect, 
alter the balance between coagulation and anticoagulation, resulting in wide-ranging 
therapeutic applications. 
3.1 Fibrinolytic enzymes from animals 
Earthworms have been used for their antithrombotic effect in East Asia traditional fork 
medicine for a thousand years. However, their precise physiological and biochemical 
mechanism remains unclear. In this century, applications of earthworms have been 
investigated intensively. In 1991, lumbrokinase (LK), a proteolytic enzyme, was first 
extracted from the Lumbricus rubellus by Mihara et al. (Mihara et al., 1991). Studies of LK 
demonstrated that these enzymes, which have a molecular weight of 25-32 kDa, found in the 
earthworm’s body cavity and digestive organs, perform PA and plasmin activities. Recent 
studies have shown that LK enzymes can dissolve blood fibrin clots and inhibit platelets 
activation and aggregation, such that LK enzymes can be administered to treat stroke 
patients as well those with cardiovascular diseases (Nakajima et al., 1993; Tang et al., 2002). 
In 2008, absorption and efficacy of earthworm fibrinolytic enzyme d (EFE-d) was enhanced 
when delivered in water-in-oil (w/o) microemulsions to rats (Cheng et al., 2008). Intestinal 
absorption experiments for LK enzymes have also showed that these heterologous 
proteolytic enzymes have potent properties, facilitating their development as anti-
thrombotic drugs (Fan et al., 2001). 
Many snake venoms, which consist of a multitude of biologically active proteins and peptides, 
are lethal to humans by adversely altering haemostasis. These biological molecules have been 
classified as serine proteases, metalloproteinases, C-type lectins, disintegrins and 
phospholipases. Each may act selectively on different blood coagulation factors, blood cells, 
and tissues (Clemetson et al., 2007). Venom proteases may involve activation or inactivation of 
each factor related to coagulation and fibrinolysis. Notably, a thrombin-like function, which 
stimulates fibrinogen forward clotting processes, and a fibrino(geno)lytic function which can 
digest fibrin and fibrinogen, also exist in snake venoms. Further study has showed that venom 
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contains two groups of fibrino(geno)lytic enzyme, with molecular masses of approximately 25 
and 60 kDa, respectively. Fibrino(geno)lytic enzymes have been isolated in snake venom, 
including those of Agkistrodon acutus, A. contortrix, A. rhodostoma, A. halys brevicaudus, A. 
piscivorus piscivorus, A. piscivorus conami, and Crotalus atrox. The most significant characteristic 
of the amino acid composition of an enzyme is very high levels of Asx and Glx residues (Hahn 
et al., 1995). Swenson and Markland (2005) characterized venom fibrino(geno)lytic 
metalloproteinases and serine proteinases. Two sub-classes of proteinases that have distinct 
sensibility to enzymatic inhibitors, such as EDTA, a metalloproteinase inhibitor, and 
phenylmethanesulfonylfluoride (PMSF), a serine proteinase inhibitor. The mechanism of 
action of venom fibrin(ogen)olytic metalloproteinases and serine proteinases differs, and they 
target different amino acid sequences in fibrin(ogen). The ǂ-chain and ǃ-chain fibrinogenases 
can be defined as venom enzymes degrading preferentially (although not exclusively) either 
the ǂ- or ǃ-chain of fibrinogen, respectively (Swenson & Markland, 2005). Recently, several 
venom fibrin(ogen)olytic enzymes and genetically recombined venom fibrin(ogen)olytic 
enzymes have been examined using animal models and a promising result was obtained 
(Gasmi et al., 1997; Marsh & Fyffe, 1996; Moise & Kashyap, 2008; Toombs, 2001). Based on the 
high fibrinolytic activity of the fibrinolytic enzyme process in venom, these enzymes are 
currently examined under examination in preclinical and clinical experiments for their 
thrombolytic efficacy and haemostatic safety. 
3.2 Fibrinolytic enzymes from microbial 
Peng et al. (2005) presented an overview of microbial fibrinolytic enzymes. Microbial 
fibrinolytic enzymes are derivatives from bacteria (e. g. streptomyces, actinomyces, and 
bacilli), fungi, and algae (Peng et al., 2005). Two well-known plasminogen activators, 
streptokinase and staphylokinase from Streptococcus hemolyticus and Streptococcus aureus, 
were demonstrated to be effective in thrombolytic therapy. In 1997, the streptokinase gene 
was cloned and its expression in the non-pathogenic Escherichia coli was characterized. The 
recombinant 47.5 kDa protein corrected to native streptokinase has a peptide sequence that 
was successfully used to treat Thrombus (Avilan et al., 1997). Unlike native streptokinase, 
the recombinant forms of streptokinase have low antigenicity and high fibrin-selective 
activity in human circulatory system (Collen & Lijnen, 1994). The recombinant fibrinolytic 
enzyme produced by recombinant technology is now mass-produced. Additionally, the side 
effect of the recombinant fibrinolytic enzyme is reduced. 
Studies of fermented foods showed that fibrinolytic enzymes may be purified from such 
sources as Japanese Natto, Korean Chungkook-Jang soy sauce, dochi, fermented shrimp 
paste, salt-fermented fish, fermented vegetables (e.g., Kimchi), and Indonesia soy products 
(e.g., Tempeh). Most fermented foods are derived from raw materials such as beans, grains, 
fish, meat, vegetables, and dairy products. Fermentation is carried out by edible bacteria or 
fungi (Kim et al., 1996; Sugimoto et al., 2007; Sumi et al., 1987; Sumi et al., 1995; Wong & 
Mine, 2004). For example, the Bacillus genus contains microbial species that usually are used 
for fermentation during fermented-foods production. Natto a popular soybean food in 
Japan, is fermented by the microorganism Bacillus subtilis natto. The first commercial 
fibrinolytic enzyme, Nattokinase (NK), was purified and characterized from Natto. 
Nattokinases, which were found with fibrin and plasmin substrate H-D-Val-Leu-Lys-pNA 
(S-2251) digestion activity (Sumi et al., 1987), have been investigated extensively worldwide.  
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In 1993, NK was characterized as a substilin-like serine protease, base on its high sensitivity to 
protein substrate Suc-Ala-Ala-Pro-Phe-pNA for substilin (Fujita et al., 1993). In 2005, a novel 
NK protein (NKCP) with both antithrombotic and fibrinolytic effects was discovered. Dose-
dependent prolongations of both prothrombin time (PT) and active partial thromboplastin 
time (APTT) were observed in rats administered NKCP intraduodenally (Omura et al., 2005). 
Two fibrinolytic enzymes, QK-1 and QK-2, from supernatant of B. subtilis QK02 culture broth 
were purified and characterized in 2004; QK-1 is a plasmin-like serine protease and QK-2 is a 
subtilisin family serine protease (Ko et al., 2004). A strong fibrinolytic subtilisin doenjang (DJ)-
4 was purified from doenjang, a traditional Korean fermented soybean paste (Kim & Choi, 
2000). Fibrinolytic recombinant full-subtilisin DJ-4 (rf-subDJ-4) and mature-subtilisin DJ-4 (rm-
subDJ-4) were expressed by a pET29 vector system (Choi et al., 2004). The rf-subDJ-4 had 
higher heat- and acid-resisting (pH 3.0–4.0) properties than native subtilisin DJ-4. Notably, rf-
subDJ-4 has the same abilities as the hydrolyzed ǂ-, ǃ-, and Ǆ-chains of fibrinogen; however, 
rm-subDJ-4 does not. Sumi et al. (1990) further demonstrated that Natto or NK capsules 
administered orally enhance fibrinolysis in canine plasma. NK has great potential as a drug 
candidate for treating and preventing thrombus in animal models (Fujita et al., 1995; Sumi et 
al., 1990). Moreover, as the fibrinolytic enzyme was purified from common edible sources, oral 
administration is likely safe. 
4. Mushroom fibrinolytic enzymes 
The fruiting body of mushrooms can produce and disperse a large number of spores within 
a short period. Spores may create new individuals when in an environment suitable for 
growth. Previously, the fruiting body was cultured in growing mediums comprising 
woodchips, straw, sawdust, coffee grounds, logs, and similar organic items. However, after 
seeding spores or the mycelium of fungi on artificial solid or liquid culture medium under 
controlled temperature and moisture, now desired mushroom cultures can be successfully 
created. The products of mushroom cultivation include hyphae, mycelium, fruiting body, 
culture broth, and derivatives that dissolve in broth. Many fibrinolytic enzymes were 
discovered from these products recently. Table 1 lists fibrinolytic enzymes derived from 
mushrooms. 
4.1 Fibrin(ogen)olytic enzyme of mushroom 
The proteolytic complex from fungus Flammulina velutipes was studied by gel 
chromatography and the activities of the enzyme complex were compared with those of 
Aspergillus terricola and Streptomyces griseus proteinases (Morozova et al., 1982). This was the 
first study of fibrinolytic enzyme from mushrooms and their application as therapeutic 
agents. Thereafter, fibrin(ogen)olytic proteases were discovered in the fruiting of Pleurotus 
ostreatus, Armillaria mellea, Tricholoma saponaceum, and Cordyceps militaris (Choi & Shin, 1998, 
Kim & Kim, 1999, 2001; Kim et al., 2006). The mushroom fruiting body can be collected from 
nature and cultured via a sterilized growth medium made of organic substances for 
saprophytic utilization. Since air, ground, plants (e.g., trees) and ground water can be 
pollute, non-polluted substances for growing mediums are becoming rare. Moreover, 
cultivation of mushroom fruiting body is space occupied and labor-intensive. In the last 
decade, technology for mushroom submerged path culture has been established in the 
laboratory and at an industrial level. Mushrooms (fungi) may generate a new generation  
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Mushroom Protease 
Fibrinogen 
Degradation 
Native 
Mol. Wt. 
Reference 
From fruiting body 
Flammulina velutipes Two protease 
(no name) 
N* N (Morozova et al., 1982) 
Pleurotus ostreatus Metalloprotease ゠ 24 kDa (Choi & Shin, 1998) 
Armillaria mellea Metalloprotease ゠ 18.5 kDa (Kim & Kim, 1999) 
Tricholoma saponaceum TSMEP1 ゠ 18.1 kDa (Kim & Kim, 2001) 
Cordyceps militaris no name ゠ 52 kDa (Kim et al., 2006) 
From mycelium 
Ganoderma lucidum metalloprotease N 100 kDa (Choi & Sa, 2000) 
Armillaria mellea AMMP ゠ 21 kDa (Lee et al., 2005) 
Flammulina velutipes FVP-1 ゠ 37 kDa (Park et al., 2007) 
Perenniporia fraxinea metalloprotease ゠ 42 kDa (Kim et al., 2008) 
From culture broth 
Fomitella fraxinea FFP1 
FFP2 
゠ 
゠ 
32 kDa 
42 kDa 
(Lee et al., 2006) 
Cordyceps sinensis CSP ゠ 31 kDa (Li et al., 2007) 
Fusarium sp. BLB FP N 27 kDa (Ueda et al., 2007) 
Schizophyllum commune no name ゠ 21.32 kDa (Lu et al., 2010a) 
From recombinant source 
Fusarium sp. BLB FP N 28.5 kDa (Sugimoto et al., 2007) 
* N means undetermined 
Table 1. Fibrinolytic enzymes derived from mushrooms 
when a fresh environment and nutrients are provided. The mycelium may grow stably 
without pollutants. Choi and Sa (2000) isolated a metalloprotease with fibrinolytic activity 
from cultured mycelium of Ganoderma lucidum (Choi & Sa, 2000). In the following decade, 
fibrin(ogen)olytic proteases from mushroom mycelium, including metalloprotease from A. 
mellea (AMMP), metalloprotease from F. velutipes FVP-1, and metalloprotease from 
Perenniporia fraxinea, were identified (Kim et al., 2008; Lee et al., 2005; Park et al., 2007). 
Fibrinolytic metalloproteases are sensitive to metalloprotease inhibitors (e.g., EDTA and 
1,10-phenanthroline) and metal ions. 
Mushrooms grown in medium or submerged broth may differ morphologically. Nutrients and 
differences between growth mediums and submerged broth contribute to the particular 
metabolite of mushrooms. Fukushima et al. (1991) reported that when soy sauce oil was the 
carbon source for Asperyillus oryzae, protease secretion was increased significantly during 
submerged cultivation. Furthermore, specific protease production was stimulated selectively 
by the oils (Fukushima et al., 1991). Changing culture medium parameters, such as osmotic 
pressure, salt concentrations, protein content, and the carbon source, markedly alter the 
extracellular performance of fungi mycelium (Archer et al., 1995; Archer & Peberdy, 1997; 
Bobowicz-Lassociska & Grajek, 1995; Kadimaliev et al., 2008). Broth for submerged cultivation 
is rich in mushroom derivatives. Over the last 50 years, mushroom derivatives with biological 
activities for humans have been investigated extensively. Several extracellular fibrinolytic 
enzymes have been purified from submerged broth of Fomitella fraxinea (i.e., FFP1 and FFP2), 
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Cordyceps sinensis (i.e., CSP) and S. commune (Lee et al., 2006; Li et al., 2007; Lu et al., 2010a; 
Ueda et al., 2007). Previous studies have demonstrated that the fibrinolytic enzymes may be 
available in the fruiting bodies of some mushrooms but not in the cultured mycelium (Kim et 
al., 2008). The purification stratagem for these extracellular fibrinolytic enzymes differs from 
those of fruiting bodies or mycelium. Fungi derivatives in submerged broth are biological 
molecules considered important for human health (Papagianni, 2004). 
Ueda et al. (2007) first purified a fibrinolytic protease from Fusarium sp. BLB (FP), and 
identified the N-terminal amino acid (Ueda et al., 2007). Sugimoto et al. (2007) cloned an FP 
gene encoding a novel protease derived from Fusarium sp. BLB. The hydrolytic activity of FP 
toward synthetic peptide subtracts is higher than that of proteases from Bacillus subtilis 
natto, Aspergillus oryzae, Streptomyces griseus and commercial plasmin (Sugimoto et al., 2007). 
This development of FP from Fusarium sp. BLB may demonstrate that manufacturing 
mushroom fibrinolytic enzymes may be possible in the future. Extracellular secreted 
protease of fungi is in some cases the fungi metabolite that may reflect cultivation 
conditions. Nutrition and the physical environment may be the dominant factor for growth 
of fungi and the rate at which extracellular proteases are produced in a submerged culture 
system. Base on the critical influence that produce mushroom extracellular secreted protease 
in submerged culture system, we expect that the high production efficiency of mushroom 
fibrin(ogen)olytic enzymes can be achieved by well-designed cultivation processes. 
4.2 Characteristics of medicinal mushroom fibrin(ogen)olytic enzymes 
Fibrin(ogen)olytic enzymes including those from P. ostreatus, A. mellea, T. saponaceum, C. 
militaris, G. lucidum, P. fraxinea, F. fraxinea, C. sinensis, F. velutipes, Fusarium sp. BLB, and S. 
commune, have been identified. Table 2 lists their biochemical properties, including 
molecular weight, optimal pH, thermal stability, inhibitors, and substrate specificity. The N-
terminal sequences of most fibrinolytic enzymes have been determined. These 
fibrin(ogen)olytic enzymes, except for metalloprotease derived from A. mella fruiting body 
and mycelia, have markedly different N-terminal sequences. The optimal pH for these 
mushroom fibrin(ogen)olytic enzymes is 5-10; the optimal temperature is 20-60°C. An 
overview of microbial fibrinolytic enzymes (Table 2) showed that mushroom fibrinolytic 
enzymes may be classified as serine protease (i.e., inhibited by serine protease inhibitors) 
and metalloprotease (i.e., inhibited by metalloprotease inhibitors) according to protease 
inhibitor specificity. 
The protease activity of mushroom serine fibrinolytic enzymes can be irreversibly inhibited by 
PMSF but no other protease inhibitors. Previous studies have showed that most fibrinolytic 
serine protease from traditional fermented foods belong to subtilisin of Bacillus origin such as 
nattokinase, subtilisin DFE and subtilisin QK-1 (Peng et al., 2005). Via study of N-terminal 
sequence alignment; a chymotrypsin-like serine protease from mushroom C. militaris had high 
sequence identify with subtilisin PR1J (GeneBank, CAC95048) (Kim et al., 2006); FFP1 from F. 
fraxinea also has 20% identify with Nattokinase and subtilisin E (Lee et al., 2006). Serine 
fibrinolytic enzymes from mushrooms of F. fraxinea (i.e., FFP1), Fusarium sp. BLB (i.e., FP), and 
C. sinensis (i.e., CSP) were found to have a broad substrate specificity for synthetic substrates, 
which including fibrin, fibrinogen, casein, substrates for subtilisin and substrates for plasmin. 
In laboratory works, fibrinolytic protease from Fusarium sp. BLB had higher fibrin degradation 
and plasminogen activation than Nattokinase (Sugimoto et al., 2007). 
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Mushroom 
Protease 
Optimal 
pH and 
temperature 
Ion  
induced 
Ion 
inhibit 
Fibrinogen 
degrade 
Protein 
inhibitor 
N- 
Terminal 
sequence 
Reference 
Serine protease type- 
Cordyceps 
militaris (52 kDa ) 
pH 7.4, 37°C Ca, Mg Cu, Co YES PMSF, 
PMASF 
Yes (Kim et al., 
2006) 
Fomitella fraxinea 
(32 kDa, FFP1) 
pH 10, 40°C N℧ N Yes PMSF, 
aprotinin 
Yes (Lee et al., 
2006) 
Cordyceps sinensis 
(31 kD, CSP) 
pH 7, 40°C N Mn, Cu, 
Hg 
Yes PMSF Yes (Li et al., 
2007) 
Fusarium sp. BLB 
(27 kDa, FP) 
pH 9.5, 50°C N N N DFP, PMSF Yes (Ueda et al., 
2007) 
Fusarium sp. BLB 
(28.5 kDa, FP) 
N N N N N Yes (Sugimoto et 
al., 2007) 
Metalloprotease type-- 
Flammulina 
velutipes 
(metalloprotease) 
N N N N EDTA N (Morozova et 
al., 1982) 
Pleurotus 
ostreatus (24 kDa, 
metalloprotease) 
pH 7.5~8.0, up 
to 50°C 
Zn, Co N Yes 1,10-
phenanthr
oline 
N (Choi & Shin, 
1998) 
Armillaria mellea 
(18.5 kDa, 
metalloprotease) 
pH 7, 45~55°C Zn, Co, 
Mg 
Hg Yes 1,10-
phenanthr
oline, 
EDTA 
Yes (Kim & Kim, 
1999) 
Ganoderma 
lucidum (100 
kDa, 
metalloprotease) 
pH 7.0~7.5, up 
to 60°C 
Zn, Co N Yes 
(assume) 
1,10-
phenanthr
oline, 
EDTA 
N (Choi & Sa, 
2000) 
Tricholoma 
saponaceum (18.1 
kDa, TSMEP1) 
pH 7.5~9, 
30~40°C 
Zn, Co, 
Mg,Fe 
Hg, Cu Yes 1,10-
phenanthr
oline, 
EDTA 
Yes (Kim & Kim, 
2001) 
Armillaria mellea  
(21 kDa, AMMP) 
pH 6, 33°C Ca, Mg Cu, Co Yes EDTA Yes (Lee et al., 
2005) 
Fomitella fraxinea 
(42 kDa, FFP2) 
pH 5, 40°C Zn, Co Cu, Ni Yes 1,10-
phenanthr
oline, 
EDTA 
Yes (Lee et al., 
2006) 
Flammulina 
velutipes (37 kDa, 
FVP-1) 
pH 6, 20~30°C Mn,Mg Cu, Fe2+, 
Fe3+ 
Yes EDTA, 
EGTA 
Yes (Park et al. 
2007) 
Perenniporia 
fraxinea (42 kDa, 
metalloprotease) 
pH 6, 35~40°C Mn, Mg Cu,Fe,Zn Yes EDTA Yes (Kim et al., 
2008) 
Schizophyllum 
commune  
(21.3 kDa, 
metalloprotease) 
pH 5, 45°C Mg Hg, Cu, 
Co 
Yes EDTA Yes (Lu et al., 
2010) 
*N means undetermined. 
Table 2. Review of medicinal mushroom fibrin(ogen)olytic enzymes 
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Mushroom fibrinolytic metalloproteases were discovered in F. velutipes, P. ostreatus, A. 
mellea, G. lucidum, T. saponaceum, F. fraxinea, P. fraxinea and S. commune (Choi & Shin, 1998; 
Kim & Kim, 1999, 2001; Kim et al., 2008; Lee et al., 2005, Lee et al., 2006; Lu et al., 2010; 
Morozova et al., 1982; Park et al., 2007). Proteases were purified in the fruiting body, or 
mycelium, or culture supernatant. The presence of Zn2+ was detected in metalloprotease 
from P. ostreatus and G. lucidum by mass spectrometry; both of these metalloproteases have 
Zn2+-dependent protease activity. Additionally, Zn2+-dependent protease activity exists in 
metalloprotease derived from F. fraxinea (FFP2), A. mellea and T. saponaceum (TSMEP1), with 
an undefined ion structure. Mg2+-dependent protease activity was found in 
metalloproteases from F. velutipes (FVP-1), A. mellea (AMMP), P. fraxinea and S. commune. 
The activity of mushroom fibrinolytic metalloproteases can be inhibited by EDTA and 1,10-
phenanthroline predominantly . The metal ions dependent activity is not only a character of 
mushroom fibrin(ogen)olytic enzymes but also can be considered as a critical point for 
proteases under the clinical application for thrombolytic therapy (Lu & Chen, 2010). 
5. Production, purification and characterization of mushroom fibrinolytic 
enzymes 
Streptokinase (SK) from streptococci is a widely used therapeutic agent for acute myocardial 
infarction. However, the manufacturing capacity of SK from haemolytic streptococci is 
limited with a high price tag. Pharmacological uses of SK take risks of causing potential 
myocardium and liver damages due to the residual bacteriohemolysin in the manufacturing 
process (Zhang et al., 1999). Peng et al. (2005) illustrated that microbial fibrinolytic enzymes, 
especially those from food-grade microorganisms, have potential to be developed as 
functional food additives and drugs to prevent or cure thrombotic disease (Peng et al., 2005). 
Therefore, fibrin(ogen)olytic enzymes from non-toxic mushrooms has gradually become the 
centre of attention for investigators in thrombolytic therapy. Mushroom of S. commune is a 
ubiquitous white rot and widespread fungus in existence. This medicinal mushroom has 
been an additive in traditional folk medicine and the subject of genetic analysis. The 
production, purification and characterization of an fibrin(ogen)olytic protease from S. 
commune were discussed in this section (Lu et al., 2010a; Lu et al., 2010b; Lu & Chen, 2010). 
The fast growing and easy cultivation raise the universal uses for S. commune in science 
researches and medicinal applications. 
5.1 Submerged cultivation of S. commune 
Schizophyllum commune derivatives have been suspected with antithrombotic effect for 
human beings by scientists (Okamura-Matsui et al., 2001), yet the detail mechanism is 
unclear. Base on the high protease and extracellular biological substance production ratio in 
submerged cultivation (Desrochers et al., 1981), S. commune is a good biological resource for 
scientists whom study the functional substance. In our study, S. commune was cultured in 
YM agar plate (contains peptone, malt extract, dextrose, yeast extract and 0.2% agar) at 25°C 
for one week. The mycelia grew and covered plate surface, was like white flannelette. 
Surface of plate agar was pure colour and without contamination. As a seed culture, a piece 
of plate agar covered with grown mycelia, was transferred to 50ml YM broth for 5 days at 
25°C. For mass production, the seed culture then transferred to 15L YM broth for additional 
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7 days with shaking platform and air exchangeable cover. Colonies of fungi in submerged 
cultivation grow exponentially, that is different from yeast cells grow at a constant rate. The 
growth rate increases with time so that the logarithm of the amount of fungus mycelium 
increases with time. 
5.2 Purification of fibrinolytic enzyme from S. commune 
Mycelia in submerged culture broth were removed by centrifugation at 4°C, 8,200 ×g, for 
30min. The supernatant was filtered by 0.45μm membrane and fractionized by cross-flow 
filtration, to collect the <100-kDa fraction, which was further concentrated by 3-kDa ceramic 
column filtration. Due to the extracellular polysaccharide with huge molecular weight 
present in broth, that will obstruct the protein purification. The ceramic cross-flow filtration 
is done before protein precipitation. Protease purification was then performed by fast 
performance liquid chromatography. The protein concentration of each eluted fraction was 
detected with A280 in real time by ÄKTA purifier 10 (GE Healthcare). Measuring activity to 
azocasein is a general selected detection method to identify target protease fractions. 
Combination of liquid chromatography and protease activity screening, the purified fraction 
containing target protease is available. 
The concentrated fraction (molecular weight 3 -100 kDa) was precipitated by saturated 
ammonium sulfate at 4°C for 8 hour followed by centrifugation at 10,000×g, 30min at 4°C. 
The protein pellet was dissolved in ddH2O and followed by dialysis with FPLC column 
buffer containing 50mM sodium phosphate (pH 8.0) and 1M (NH4)2SO4 as 1st dialysis 
substrate. In step 1, a hydrophobic interaction column, Phenyl SepharoseTM High 
Performance beaded packing column was preequilibrated with column buffer. Equilibrated 
1st dialysis substrate was loaded on column at flow rate of 1 ml/min. Figure 1A illustrated 
the result of elution processes with column buffer without (NH4)2SO4 in a stepwise manner 
of 60 min interval at flow rate of 1 ml/min. Eluted fractions were analyzed for protease 
activity to azocasein and recorded (Fig. 1A). The active fractions were pooled; protein 
precipitated and dialyzed against 20mM Tris (pH 8.0) as 2nd dialysis substrate for next step 
of chromatography.  
In step 2, an ion exchange column, Mono QTM 5/50 GL column was preequilibrated with 
20mM Tris buffer (pH 8.0). The 2nd dialysis substrate was loaded on Mono QTM 5/50 GL 
column at flow rate of 1 ml/min. Elution was carried out with the same buffer but 
containing 1M NaCl, by linear gradient of 20-fold column volume to 40% 1M NaCl. After 
examination of protease activity to azocasein (see in Fig. 1B), the active fractions were 
pooled; protein precipitated and dialyzed against 50mM sodium phosphate buffer (pH 8.0) 
as 3rd dialysis substrate for next step of chromatography. 
In step 3, a size exclusion column, Superdex 75 10/300 GL column was preequilibrated with 
50mM sodium phosphate buffer. The 3rd dialysis substrate was loaded with same buffer at 
flow rate of 1.2 ml/min. Eluted fractions were analyzed for protease activity to azocasein 
(see in Fig. 1C). Figure 2 showed the purification purity by SDS-PAGE (Fig. 2). The purified 
protease then can be applied for more. 
Fibrinolytic enzyme purification from mushroom may divide into two processes. One is the 
pre-treatment of resource, including the crude protein extraction from fruiting body, or 
mycelium, or culture supernatant. Another is the chromatography stratagem, which 
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including the combination of ion exchange, hydrophobic interaction and size exclusion 
chromatography. Techniques with selectivity are highly independent of protease resources 
and the enzyme properties. 
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Fig. 1. Chromatography purification of S. commune fibrinolytic enzyme (A) Eluted fractions 
of Phenyl SepharoseTM High Performance column; (B) Eluted fractions of Mono Q column; 
(C) Eluted fractions of Superdex 75 10/300 GL column. 
 
Fig. 2. SDS-PAGE result of chromatographic purification M: protein markers; Lane 1: 1st 
dialysis substrate; Lane 2: 2nd dialysis substrate; Lane 3: 3rd dialysis substrate; Lane 4: 
Protein with highest protease activity eluted from Superdex 75 10/300 GL column. 
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5.3 Characterization of fibrinolytic enzyme from S. commune 
To study the effects of pH and temperature to fibrinolytic enzyme from S. commune, purified 
enzyme was incubated in various pH and temperature respectively, and the protease 
activity to azocasein then examined. Optimal protease activity reveal at pH 5.0 and 45°C, the 
data was illustrated in Fig. 3A and 3B.  
 
 
Fig. 3. The effects of pH and temperature on protease activity of fibrinolytic enzyme from S. 
commune (A) pH effects; (B) Temperature effects. 
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Three replicates of fibrinolytic enzyme were mixed with HgCl2, C4H6O4Zn·2H2O, CuSO4, 
MgCl2, CoCl2, CaCl2, Pb(NO3)2, ddH2O (control) and protease inhibitors of PMSF (serine 
protease inhibitor), EDTA (metalloprotease inhibitor), benzamidine hydrochloride hydrate 
(trypsin, trypsin-like protease inhibitor), pepstatin A (aspartyl peptidases inhibitor), aprotinin 
(serine protease) and phosphoramidon (endopeptidase inhibitor) respectively. Protease 
activity of mixed solution was then examined by azocasein assay. Figure 4 demonstrated the 
relative protease activity to the control treatment (100%=1) (Fig. 4A & 4B). The result indicated 
that the protease shows Mg2+-dependent activity, and inhibits by EDTA. 
 
 
Fig. 4. The effects of divalent cations and protein inhibitors on protease activity of 
fibrinolytic enzyme from S. commune (A) Divalent cations effects; (B) Protein inhibitors 
effects. 
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N-terminal sequence of protease is another character for protein identification. However, 
fibrinolytic enzymes from microorganisms show low homology except the fibrinolytic 
enzyme from substilisin group, such as substilisin NAT (Nakamura et al., 1992) , substilisin 
E (Wong et al., 1984), substilisin DFE (Peng et al., 2003). Table 3 illustrated the results of N-
terminal sequence comparison; it demonstrated the distinctive feature of the fibrinolytic 
enzyme from S. commune to other mushroom. 
 
Enzyme1) N-terminal amino acid sequence 
NK & substilisin DFE A Q S V P Y G I S 
GFMEP  T Y N G C S S S 
POMEP A T F V G C S A  
AMMEP X2) X Y N G X T X  
TSMEP A L Y V G X S P  
Fibrinolytic enzyme from S. commune A S Y N G X S S  
(1) GFMEP, POMEP, AMMEP and TSMEP are metalloendopeptidases from Grifola frondosa, Pleurotus 
ostreatu, Armillariella mellea and Tricholoma saponaceum. (2) X means amino acid undetermined. 
Table 3. Comparison of N-terminal amino acid sequence of mushroom fibrinoytic enzyme 
6. Antithrombotic effect of mushroom fibrinolytic enzymes 
Current clinical thrombolytic agents are used to convert plasminogen to active enzyme, 
plasmin, which degrades fibrin and process antithrombotic effect. It’s an effective way to 
decompose harmful thrombus in circulation system, but the side effect, the excess 
stimulation of plasmin that may cause haemorrhage within patients. Newly thrombolytic 
agents now are developed for fibrin-specific property, acting on the surface of thrombus that 
avoids excessive induction of systemic fibrinolytic system. Fibrinolytic enzymes from 
medicinal mushroom are novel proteases with fibrin and fibrinogen degradation activity, 
which directly break the clot and interfere the clotting system. In order to identify the 
clinical functions and risks of medicinal mushroom fibrinolytic enzymes; mushroom 
fibrinolytic enzymes were examined by various antithrombotic examinations, such as 
fibrinolytic assay, fibrinogenolytic assay, plasminogen activation assay, and the dynamic 
tracking of blood clot formation.  
6.1 Fibrinolytic activity assay and clot degradation test 
Fibrinolytic activity was determined by artificial fibrin plate assay, which synthesized by the 
method described by Astrup and Mullertz (Astrup & Mullertz, 1952). Fibrin plate was made 
at room temperature in a petri dish containing 1.5% agarose, 0.2% human fibrinogen, and 
10U thrombin. Purified protease were loaded on a fibrin plate, and incubated for 24 hours. 
Plasmin from human plasma (3U/mg protein) was applied as a positive control. The result 
showed that the purified S. commune fibrinolytic enzyme display stronger fibrinolytic 
activity than commercial plasmin (Fig. 5).  
Rat blood was withdrawn without anticoagulant and stayed for clot formation in a tube. A 
piece of clot was placed on Petri dish, followed by dropping 0.2μg and 0.5μg fibrinolytic 
enzyme on clot disks and incubated in 20°C for 8 hours to observe the clot degradation 
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effects. Phosphate buffer was dropped on clot disk as the control treatment and another clot 
disk as the blank without any treatment. Figure 6 demonstrated that S. commune fibrinolytic 
enzyme digests the blood clot dominantly (Fig.6). 
 
Fig. 5. Fibrinolytic activity of the fibrinolytic enzyme from S. commune Fibrin digestion zones 
A, B, C, and D: 0.2, 0.5, 0.8, and 1.0μg of human plasmin, respectively. Fibrin digestion zones 
E, F, G, and H: 0.1, 0.25, 0.5, and 1μg of fibrinolytic enzyme S. commune, respectively. 
Treatment of 1.0μg human plasmin (zones D) showed the equal digestion effects to 0.5μg 
fibrinolytic enzyme from S. commune (zone G). 
 
Fig. 6. Clot degradation assay of fibrinolytic enzyme from S. commune 0.2μg and 0.5μg: 
blood clot disks treated with 0.2μg and 0.5μg fibrinolytic enzyme; Control: clot disk treated 
with PBS; Blank: blank blood clot disk. Treatment of 0.2μg and 0.5μg fibrinolytic enzyme 
digested the clot disks, but opposite results were observed in control and blank. 
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6.2 Fibrinogenolytic activity assay 
A fibrinogenolytic degradation assay was performed using a 1% fibrinogen solution mixed 
with the protease from S. commune at 37°C. At different time intervals, the reaction mixture 
was removed and SDS-PAGE electrophoresis was performed. Fibrinogen is composed of 
peptides ǂ-, ǃ- and Ǆ-chains, and shows three bands on the SDS-PAGE. The fibrinogenolytic 
activity assay was carried out by the incubation of fibrinolytic enzyme with fibrinogen. 
Significant degradation of the fibrinogen ǂ-chain and ǃ-chain occurred within 0.5 hour after 
the reaction. Degradation of the Ǆ-chain occurred after 6 hours of incubation. Most of the Ǆ-
chain was digested after 22 hours of incubation. Afterward, the fibrinolytic enzyme 
completely digested all of peptide chains in 30 hours. Fibrinolytic enzyme from S. commune 
displayed a higher activity in digesting the ǂ-chain and ǃ-chain, and it was less efficient in 
digesting the Ǆ-chain (Fig. 7). 
 
Fig. 7. Fibrinogenolytic assay of the fibrinolytic enzyme from S. commune ǂ, ǃ and Ǆ means : 
ǂ, ǃ, and Ǆ-chains of fibrinogen. M: Protein marker. Lane 1~7: Time course sampling in 
reaction. Black arrows: Fibrinogen degradation products. 
6.3 Plasminogen activation assay 
Plassminogen activation assay was performed by incubating 12.5μg purified enzyme with 
plasminogen (0.1UN) and a 10mM plasmin-specific substrate S2251 at 37°C. Substrate S2251 
can be cleaved by plasmin and generated measurable p-nitroaniline (p-NA). In this assay, 
human plasmin and urokinase were used as positive control for S2251 digestion and 
plasminogen activation. In this assay, fibrinolytic enzyme from S. commune was mixed with 
plasminogen, plasmin substrate S2251and without fibrin. As the results in Fig. 8, the 
presence of urokinase, which is known to activate plasminogen, resulted in the digestion of 
S2251 and an increase in absorbance. The purified fibrinolytic enzyme from S. commune 
failed to digest the S2251 directly and without plasminogen activation activity. 
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Fig. 8. Plasminogen activation assay of fibrinolytic enzyme from S. commune ○ : 1 μg 
purified enzyme and plasminogen at 0.0001 UN. ■ : 1 μg urokinase and plasminogen at 
0.0001 UN. □ : 1 μg purified protease. ＊ : 1 μg human plasmin (≧3 units/mg protein). ᇞ : 
plasminogen at 0.0001 UN. ● : 20 μg urokinase. 
In order to test the plasminogen activation while fibrin present, fibrinolytic enzyme from S. 
commune was applied on a plasminogen-rich fibrin plate containing 0.1UN plasminogen. 
The protease-digested zone in the plasminogen-rich fibrin plate was then compared to that 
of the plasminogen-free fibrin plate. In the presence of fibrin, digest representation were 
equal on the plasminogen-rich and plasminogen-free plates (data not shown). Fibrinolytic 
enzyme from S. commune is not a serine protease for S2251 and does not activate 
plasminogen in vitro, regardless of whether fibrin exists or not. 
6.4 Coagulation effects of protease from S. commune 
In previous study, G. lucidum fibrinolytic enzyme was examined in human plasma by 
activated partial thromboplastin time (APTT) and thrombin time (TT). The anticoagulant 
activity was performed by inhibition of thrombin and hydrolyzation of fibrin and fibrinogen 
(Choi & Sa, 2000). In our research, S. commune fibrinolytic enzyme applied in rat citrated 
blood, and the coagulation processes were monitored by thromboelastrography (TEG®) 
analysis. Four TEG parameters, including the reaction time for clot initiation (R), the time to 
reach a 20-mm level of clot formation (K), the slope angle from R to K (ǂ value), and the 
maximum vertical amplitude of the developed clot (MA) were measured. Fibrinolytic 
enzyme from S. commune was mixed with CaCl2 and citrated rat blood to initiate 
recalcification. Fibrinolysis after MA was determined by measuring the loss of clot strength. 
Urokinase was used as positive treatment to activate plasminogen and resulted in 
fibrinolysis after reaching of MA (Fig. 9). 
The result of TEG reaction time (R) indicated that the protease did not affect the clotting 
aggregation by the platelets, since clotting initiation completed normally. Fibrinolytic 
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enzyme of S. commune suppressed blood coagulation without excessive fibrinolysis. Clotting 
time prolongation, clotting velocity depresses and significant decrease of clotting strength 
were occurred (Table 4). Coagulation suppression effect here we predicate may resulted 
from fibrinolysis and platelet-medicated clot retraction. 
 
Fig. 9. Thromboelastography tracings of citrated blood added fibrinolytic enzyme from S. 
commune and human urokinase Curve A: Human urokinase 0.5μg added. Curve B, C, D, E 
and F: Purified protease from S. commune 1.5, 1.2, 0.6, 0.3, 0 (control)μg added respectively. 
 
TEG  parameters 
Range of 
values 
Amount of fibrinolytic enzyme in TEG 
0 μg 0.3 μg 0.6 μg 1.2 μg 1.5 μg 
Reaction time (R) 2.2-4.7 min 100a 92.07 86.43 88.14 81.21 
Coagulation time (K) 0.8-3.3 min 100 96.67 97.96 127.22 165.17b 
Velocity of clot (ǂ) 50.2-81.1° 100 99.69 101.44 98.76 92.74b 
Maximum amplitude 
(MA) 
75.8-24.5 
mm 
100 94.14 90.00 73.51b 59.07b 
a TEG Parameters with the addition of protease are presented as the relative index obtained by 
normalized to the values in control sample (0μg) which are set to 100%. (n=8). 
b Statistically significant compared to control samples, P＜0.05 
Table 4. Effects of various concentrations of fibrinolytic enzyme from S. commune to citrated 
blood by thromboelastography analysis 
In an experiment of coexist with Mg2+ ion, citrated blood treated by S. commune fibrinolytic 
enzyme and Mg2+ ion. The supplementation of Mg2+ ion stimulated the depression of blood 
clot amplitude (Fig. 10). Magnesium therapy in coronary heart disease has recently been 
proposed and documented in clinical trials (Shechter et al., 1999; Whiss & Andersson, 2002). 
Additionally, magnesium ion stimulate activity of fibrinolytic enzyme from S. commune was 
proved in study. Thus, a regulatory manipulation of S. commune fibrinolytic enzyme activity 
by magnesium supplementation can be expected in the future. The cost reducing effect by 
magnesium supplementation is also an innovative ideal for the currently used fibrin-specific 
antithrombotic agents. 
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Fig. 10. Blood clot amplitude analysis of fibrinolytic enzyme coexist to Mg2+ Control: citrated 
blood mixed with PBS; Mg: citrated blood mixed with MgCl2 (2.5mM); 0.6 / 1.2μg: citrated 
blood mixed with 0.6 / 1.2μg fibrinolytic enzyme; 0.6μg&Mg: citrated blood mixed with 
0.6μg fibrinolytic enzyme and 2.5mM MgCl2. Alphabetical lowercase means significant 
variation between other treatments, a difference was considered statistically significant at p 
< 0.05. TEG values were expressed relative to the control sample (at 100%). 
7. Conclusion 
In recent decades, pharmacologic intervention of an established thrombus has become an ideal 
therapeutic approach for thrombotic occlusive disease. Clinical application of several 
plasminogen activators results in activation of circulating plasminogen, which successfully 
digest abnormal blood clot occluded in arteries or vein; however, risk accompanied with this 
treatment option may include a life-threatening haemorrhage caused by the systemic 
activation of fibrinolytic mechanism. While scientists and clinicians are in the search for a 
better, safer therapeutic agent with fewer side effects, the discovery of the fibrinolytic enzymes 
from medicinal mushroom may shed the light for the modern thrombolytic therapies.  
So far, the methods for purification and characterization of medicinal mushroom fibrinolytic 
enzyme were carried out by mushroom cultivation, crude protein extraction, protein 
chromatography, fibrin(ogen)olytic identification and characterization. Purification and 
characterization of fibrinolytic enzyme from S. commune were illustrated in this chapter, and 
might be a representative model for purification of medicinal mushroom fibrinolytic enzyme. 
Fibrin(ogen)olytic enzymes were discovered from mushrooms, such as P. ostreatus, A. mellea, 
T. saponaceum, C. militaris, G. lucidum, P. fraxinea, F. fraxinea, C. sinensis, F. velutipes, Fusarium 
sp. BLB and S. commune. Most of them have been universal dietetic additives and traditional 
fork medicine for a long time. The low antigenicity and allergic affections of these 
mushroom fibrinolytic enzymes when human taken orally may be expected definitely. In 
previous studies, many mushroom fibrinolytic enzymes were investigated which perform 
superior fibrinolytic activity than known thrombolytic agents and inhibit thrombus 
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formation. As fibrinolytic effect is not the only solution for thrombus occurrence and 
decomposition, the therapeutic effect of mushroom fibrinolytic enzyme were further 
examined in citrated blood on thromboelastography, which monitored the clotting and 
fibrinolysis action in blood. Fibrinolytic enzymes interfere in antithrombotic interaction may 
occur amongst plasma proteins, such as platelets, prothrombin, thrombin, plasminogen, 
plasmin, fibrinogen, and fibrin. As results have shown, using S. commune as the model, 
mushroom fibrinolytic enzyme suppressed blood coagulation without excessive fibrinolysis 
by prolonging clotting time and decreasing clotting velocity. Consequently, the result is a 
significant decrease in clot strength. Most notably, the initiation of clotting system and 
plasminogen activation occurrences were maintained at a normal level. Mushroom 
fibrinolytic enzyme did not offset haemostasis, but rather reduced the likelihood of 
thrombus formation without increasing the risk of haemorrhage. These data indicated that 
the safer antithrombotic effect of mushroom fibrinolytic enzyme and the board application 
may use as thrombolytic agents clinically. 
Metal ion therapy in coronary heart disease has recently been proposed. Although the 
therapeutic results are still ambivalent, the researches and therapeutic development are never 
finished to search a more effective therapy for such coronary patients. Review of characters 
from medicinal mushroom fibrinolytic enzymes, these enzymes revealed significant metal ion 
dependent activity. The inhibition or the stimulation of enzyme activity by metal ion may 
provide a pharmaceutical conservation and a critical control manipulation in clinical uses. 
Although the description in this chapter showed the investigation of mushroom fibrinolytic 
enzyme is currently at stage of in vitro and ex-vivo experiment. However, the effectiveness of 
medicinal mushroom fibrinolytic enzyme in antithrombotic assays indicated the possible 
clinical application of mushroom fibrinolytic enzyme in the future. 
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